Biotheus signs agreement with Hansoh for EGFR/MET bispecific antibody PM-1080 in China
Nov. 15, 2022
Biotheus Inc. has entered into a license and collaboration agreement with Hansoh Pharmaceuticals (Hansoh Pharmaceutical Group Co. Ltd.) for Biotheus' EGFR/MET bispecific antibody PM-1080 in Greater China, including mainland China, Hong Kong, Macao and Taiwan.